Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:


- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights


Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a wide range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax’s clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and operates a subsidiary in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc Key Recent Developments

Jun 08,2020: Novavax president of R&D Dr. Gregory Glenn to discuss the development of covid-19 vaccines on panel at 2020 BIO Digital
May 28,2020: Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing
May 11,2020: Novavax reports first quarter 2020 financial results
Mar 11,2020: Novavax reports fourth quarter and full year 2019 financial results
Feb 27,2020: Novavax starts animal testing of coronavirus vaccine candidates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Novavax Inc - Key Facts
Novavax Inc - Key Employees
Novavax Inc - Key Employee Biographies
Novavax Inc - Major Products and Services
Novavax Inc - History
Novavax Inc - Company Statement
Novavax Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novavax Inc - Business Description
Novavax Inc - SWOT Analysis
SWOT Analysis - Overview
Novavax Inc - Strengths
Novavax Inc - Weaknesses
Novavax Inc - Opportunities
Novavax Inc - Threats
Novavax Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novavax Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 08, 2020: Novavax president of R&D Dr. Gregory Glenn to discuss the development of covid-19 vaccines on panel at 2020 BIO Digital
May 28, 2020: Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing
May 11, 2020: Novavax reports first quarter 2020 financial results
Mar 11, 2020: Novavax reports fourth quarter and full year 2019 financial results
Feb 27, 2020: Novavax starts animal testing of coronavirus vaccine candidates
Jan 23, 2020: Coronavirus: Vir Biotechnology and Novavax announce vaccine plans
Nov 07, 2019: Novavax reports third quarter 2019 financial results
Aug 07, 2019: Novavax reports second quarter 2019 financial results
Jun 04, 2019: Novavax CFO John Trizzino to discuss future of influenza vaccines on industry panel at 2019 BIO International Convention
May 02, 2019: Novavax reports first quarter 2019 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Novavax Inc, Key Facts
Novavax Inc, Key Employees
Novavax Inc, Key Employee Biographies
Novavax Inc, Major Products and Services
Novavax Inc, History
Novavax Inc, Other Locations
Novavax Inc, Subsidiaries
Novavax Inc, Joint Venture
Novavax Inc, Key Competitors
Novavax Inc, Ratios based on current share price
Novavax Inc, Annual Ratios
Novavax Inc, Annual Ratios (Cont...1)
Novavax Inc, Interim Ratios
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novavax Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Novavax Inc, Performance Chart (2015 - 2019)
Novavax Inc, Ratio Charts
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.

Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against

USD 495 View Report

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

USD 125 View Report

Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.

Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against

USD 495 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available